APP and Alzheimer disease: To verify the above presented hypothesis we used transgenic mice expressing human APP with AD-causing mutations (APPswe) fed with WD from the 3rd month of age, and for the first time we tracked and characterized the detailed chronology of WD-induced systemic and metabolic alterations followed by brain Aβ pathology and neuroinflammatory changes.